Payment overview · 2025
General Payments
$439.18
21 reported records · 10 companies
Healthcare provider profile · identity verified
Umar Murad, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · CHAVIES, KY · NPI 1952391724
Verified facts
What the public records show
CMS Open Payments records show Umar Murad, M.D. received $439.18 in general payments during 2025 across 21 reported records.
Collegium Pharmaceutical, Inc. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $109.80 | 25.0% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $107.54 | 24.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.84 | 13.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.85 | 9.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.58 | 6.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.75 | 5.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.96 | 4.5% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $16.13 | 3.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.13 | 3.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.60 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.18 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $109.80 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $107.54 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.84 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 811 | 72 |
| Gabapentin | Gabapentin | 662 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 356 | 71 |
| Lisinopril | Lisinopril | 343 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 59 |
| Alprazolam | Alprazolam | 292 | 26 |
| Clonazepam | Clonazepam | 262 | 26 |
| Metformin Hcl | Metformin Hcl | 217 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 189 | 14 |
| Furosemide | Furosemide | 185 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 43 |
| Potassium Chloride | Potassium Chloride | 167 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 36 |
| Losartan Potassium | Losartan Potassium | 163 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 31 |
| Trulicity | Dulaglutide | 143 | 25 |
| Omeprazole | Omeprazole | 136 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 132 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 25 |
| Mounjaro | Tirzepatide | 124 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 20 |
| Alendronate Sodium | Alendronate Sodium | 115 | 18 |
| Simvastatin | Simvastatin | 108 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 43 |
| Methylprednisolone | Methylprednisolone | 101 | 73 |
| Allopurinol | Allopurinol | 99 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 95 | 15 |
| Eliquis | Apixaban | 89 | 20 |
| Famotidine | Famotidine | 87 | 20 |
| Nitroglycerin | Nitroglycerin | 87 | 28 |
| Meloxicam | Meloxicam | 86 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 19 |
| Montelukast Sodium | Montelukast Sodium | 78 | 11 |
| Ibuprofen | Ibuprofen | 76 | 24 |
| Nifedipine Er | Nifedipine | 76 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 30 |
| Mirtazapine | Mirtazapine | 70 | 17 |
| Ozempic | Semaglutide | 68 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | suppressed |
| Carvedilol | Carvedilol | 61 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 14 |
| Entresto | Sacubitril/Valsartan | 59 | 12 |
| Meclizine Hcl | Meclizine Hcl | 58 | 16 |
| Sertraline Hcl | Sertraline Hcl | 58 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 11 |
| Atenolol | Atenolol | 55 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Diazepam | Diazepam | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 15 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 37 |
| Promethazine Hcl | Promethazine Hcl | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 35 |
| Glipizide | Glipizide | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Ibu | Ibuprofen | 31 | 11 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 23 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Fentanyl | Fentanyl | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 15 |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Enulose | Lactulose | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.18 · 21 records | Collegium Pharmaceutical, Inc. | ABILIFY ASIMTUFII, Azstarys, CAPLYTA, INGREZZA, Jornay PM, OTEZLA, Ozempic, REPATHA, The Cologuard Plus Collection Kit, UZEDY, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error